In this study, we have identified a novel antagonist ligand of GPER, namely C4PY, which exhibits an inhibitory action on GPER-activated signaling, including the repression of both ERK and Akt phosphorylation, gene transcription, and cell proliferation and migration in breast cancer cells and in CAFs. The gene discussed is MAPK1; the disease is breast cancer.